UBS Group AG - ZENTALIS PHARMACEUTICALS INC ownership

ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 117 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.

Quarter-by-quarter ownership
UBS Group AG ownership history of ZENTALIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,340,670
-47.0%
66,833
-25.5%
0.00%
-100.0%
Q2 2023$2,531,933
+76.5%
89,753
+7.6%
0.00%0.0%
Q1 2023$1,434,635
-54.0%
83,409
-46.2%
0.00%0.0%
Q4 2022$3,119,525
+475.6%
154,892
+519.7%
0.00%
Q3 2022$542,000
-35.4%
24,995
-16.2%
0.00%
Q2 2022$839,000
-75.5%
29,843
-59.8%
0.00%
-100.0%
Q1 2022$3,426,000
+14.8%
74,255
+109.1%
0.00%0.0%
Q4 2021$2,984,000
+16477.8%
35,506
+13298.5%
0.00%
Q3 2021$18,000
+28.6%
265
+3.9%
0.00%
Q2 2021$14,000
+55.6%
255
+40.1%
0.00%
Q4 2020$9,000
-25.0%
182
-29.2%
0.00%
Q2 2020$12,0002570.00%
Other shareholders
ZENTALIS PHARMACEUTICALS INC shareholders Q3 2021
NameSharesValueWeighting ↓
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 2,426,095$111,940,0006.63%
Paradigm Biocapital Advisors LP 287,577$13,269,0003.51%
Avidity Partners Management LP 3,176,999$146,587,0003.05%
Integral Health Asset Management, LLC 215,000$9,920,0002.58%
Matrix Capital Management Company, LP 4,349,279$200,676,0002.41%
Affinity Asset Advisors, LLC 207,500$9,574,0001.53%
Ikarian Capital, LLC 202,203$9,329,0001.23%
Ghost Tree Capital, LLC 80,000$3,691,0000.80%
Eventide Asset Management 761,000$35,113,0000.55%
Perceptive Advisors 501,509$23,140,0000.46%
View complete list of ZENTALIS PHARMACEUTICALS INC shareholders